SUIT-005 O2 pfi D011: Difference between revisions
No edit summary |
No edit summary |
||
Line 8: | Line 8: | ||
::: '''[[Categories of SUIT protocols |SUIT-category]]:''' FNS(Oct,PM) | ::: '''[[Categories of SUIT protocols |SUIT-category]]:''' FNS(Oct,PM) | ||
::: '''[[SUIT protocol pattern]]:''' diametral 1OctM;2D;3P;4S;5U;6Rot | ::: '''[[SUIT protocol pattern]]:''' diametral 1OctM;2D;3P;4S;5U;6Rot | ||
The SUIT-005 protocols provide information on the [[Fatty_acid_oxidation_pathway_control_state|F-pathway]], the combined [[FN|FN]] pathway, and the convergence [[FNS |FNS]] pathways in the [[Oxidative phosphorylation|OXPHOS state]]. [[FNS |FNS]] comprises the most important pathways in many cell types and thus provides a physiologically relevant estimate of maximum [[OXPHOS-capacity| OXPHOS-]] and [[ET-capacity |ET-capacity]]. SUIT-005 can be extended with the CIV assay module. | |||
This protocol is linked to [[SUIT-002 O2 pfi D006]] - SUIT RP2, specifically for human skeletal muscle mitochondria. SUIT-005 O2 pfi D011 is harmonized with [[SUIT-004 O2 pfi D010]]. | |||
The F-pathway has to be tested previously. | |||
__TOC__ | __TOC__ |
Revision as of 19:09, 5 March 2019
Description
Abbreviation: FNS(Oct,PM)
Reference: A: SUIT-005 short protocol linked to SUIT-002 O2 pfi D006 - SUIT RP2 (human skeletal muscle)
SUIT number: D011_1OctM;2D;3P;4S;5U;6Rot;7Ama;8AsTm;9Azd
O2k-Application: O2
- SUIT-category: FNS(Oct,PM)
- SUIT protocol pattern: diametral 1OctM;2D;3P;4S;5U;6Rot
The SUIT-005 protocols provide information on the F-pathway, the combined FN pathway, and the convergence FNS pathways in the OXPHOS state. FNS comprises the most important pathways in many cell types and thus provides a physiologically relevant estimate of maximum OXPHOS- and ET-capacity. SUIT-005 can be extended with the CIV assay module. This protocol is linked to SUIT-002 O2 pfi D006 - SUIT RP2, specifically for human skeletal muscle mitochondria. SUIT-005 O2 pfi D011 is harmonized with SUIT-004 O2 pfi D010. The F-pathway has to be tested previously.
Communicated by Doerrier C, Iglesias-Gonzalez J and Gnaiger E (last update 2019-01-21)
Steps and respiratory states
Step | State | Pathway | Q-junction | Comment - Events (E) and Marks (M) |
---|---|---|---|---|
1OctM | OctML(n) | F(N) | FAO | 1OctM
|
2D | OctMP | F(N) | FAO | 1OCtM;2D
|
2c | OctMcP | F(N) | FAO | 1OCtM;2D;2c
|
3P | OctPMP | FN | F&CI | 1OctM;2D;2c;3P
|
4S | OctPMSP | FNS | F&CI&II | 1OctM;2D;2c;3P;4S
|
5U | OctPMSE | FNS | F&CI&II | 1OctM;2D;2c;3P;4S;5U
|
6Rot | SE | S | CII | 1OctM;2D;3P;4S;5U;6Rot
|
7Ama | ROX | 1OctM;2D;3P;4S;5U;6Rot;7Ama
|
Step | Respiratory state | Pathway control | ET-Complex | Comment |
---|---|---|---|---|
## AsTm | AsTmE | CIV | CIV | |
## Azd | CHB |
- Bioblast links: SUIT protocols - >>>>>>> - Click on [Expand] or [Collapse] - >>>>>>>
- Coupling control
- Pathway control
- ยป Electron transfer pathway
- ยป Fatty acid oxidation pathway control state, F
- ยป NADH electron transfer-pathway state, N
- ยป Succinate pathway control state, S
- ยป NS-pathway control state, NS
- ยป Glycerophosphate pathway control state, Gp
- ยป Complex IV single step, CIV
- ยป Anaplerotic pathway control state
- Pathway control
- Main fuel substrates
- ยป Glutamate, G
- ยป Glycerophosphate, Gp
- ยป Malate, M
- ยป Octanoylcarnitine, Oct
- ยป Pyruvate, P
- ยป Succinate, S
- Main fuel substrates
- Glossary
Strengths and limitations
- + The protocol provides information on FAO capacity in the absence of other, potentially interfering pathways, both in the LEAK state and in OXPHOS.
- + FNS OXPHOS-capacity comprises the most important pathways in many cell types and thus provides a physiologically relevant estimate of maximum mitochondrial respiratory capacity.
- + FNS ET-capacity is a good estimate of overall ET-capacity in many cell types.
- + The presence of PM and S establishes a fully operative TCA cycle activity (PMS) if the 2-oxoglutarate carrier does not outcompete the sources of 2-oxoglutarate
- + Application of the cytochrome c test early in the protocol ensures comparability of all states in case of any effect of c.
- + Reasonable duration of the experiment (1.5 to 2 h); 2-3 h when the CIV module is added.
- - F- OXPHOS-capacity may be underestimated. In human heart muscle addition of Oct to palmitoylcarnitine (Pal) + malate increased OXPHOS by 26% (Lemuieux et al 2011).
- - SRotE may be underestimated if S is not saturating.
Compare SUIT protocols
- SUIT-002
- SUIT-002 O2 pfi D006
- imt, ROX: 1OctM;2D;2c;3P;4S;5U;6Rot;7Ama
- pfi, high O2, no ROX: FNS(PM)01_pfiO2,1OctM,2D(c),3P,4S,5U,6Rot
References
MitoPedia concepts: SUIT protocol, SUIT A, Find
MitoPedia methods:
Respirometry